Q-omics provides the consensus-scored NOG profile across patient tissues and cancer cell-line models. NOG expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NOG is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, NOG RNA expression shows 15,826 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where NOG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOG survival associations across molecular data types. NOG RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOG RNA expression–survival associations across cancer types. High NOG expression shows unfavorable associations in MESO, COAD and UVM, but favorable associations in UCEC, CHOL and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify MESO as the clearest survival context for NOG RNA expression.
This table summarizes NOG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NOG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOG shows lower tumor expression in KICH, BRCA, PRAD and KIRP and higher tumor expression in KIRC and UCEC. The KIRC box plot shows higher NOG RNA expression in tumor versus normal tissue (log2 FC = +0.683, t-test p < 0.001).
This table shows molecular features associated with NOG in patient tissues and cancer cell lines. In patient samples, NOG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NOG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
